Loading…

Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds

This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil. Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical research 2001-07, Vol.18 (7), p.957-963
Main Authors: DAGENAIS, Claude, JIAN ZONG, DUCHARME, Julie, POLLACK, Gary M
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883
cites
container_end_page 963
container_issue 7
container_start_page 957
container_title Pharmaceutical research
container_volume 18
creator DAGENAIS, Claude
JIAN ZONG
DUCHARME, Julie
POLLACK, Gary M
description This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil. Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain perfusion. Brain:plasma distribution of substrates after i.v. administration was determined in both strains. Genetic disruption of mdr1a P-gp resulted in 1.3-, 6.6- and 14-fold increases in Clup for morphine, verapamil and quinidine, respectively. With the exception of small differences for verapamil, gender did not affect Clup. Saturable transport of verapamil and quinidine was observed only in P-gp-competent mice, with apparent IC50 values for efflux of 8.6 +/- 2.3 microM and 36 +/- 2 microM, respectively. Verapamil Clup was approximately 50% higher in mdr1a(+/-) vs. mdr1a(+/+) mice; no such difference was observed for quinidine. In P-gp-competent mice, uptake of verapamil and quinidine was unaffected by organic vehicles. Plasma decreased VER Clup to a greater extent in the presence of P-gp. The influence of P-gp in situ was lower than, but correlated with, the effect in vivo. P-gp decreases Clup of morphine, verapamil and quinidine in situ with little or no influence of gender, but this effect cannot fully account for the effects of P-gp in vivo. P-gp is the only saturable transport mechanism for verapamil and quinidine at the murine blood-brain barrier. The influence of protein binding on Clup may be enhanced by P-gp-mediated efflux.
doi_str_mv 10.1023/A:1010984110732
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71080124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71080124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883</originalsourceid><addsrcrecordid>eNpd0E1r3DAQBmBRWppNmnNuQZSSU9zOSLIt5RZCkhYC7aGF3MxYH8GpLW8l-7D_vlqyhRIQSIhnZvSKsTOEzwhCfrm-QkAwWiFCK8UbtsG6lZUB9fiWbaAVqtKtwiN2nPMzAGg06j07QlSmMXW9YbvbELxd-Bz45BIS_1E9jTs7b9O8-CHyJx89d0NO63YZ5ni5v3A-XXKKjue1z0uixXM7R-vj_lwQL6tPVKpLEf32--bZj2WMd0VO23mNLn9g7wKN2Z8e9hP26-72583X6uH7_beb64fKSg1Lhb2osTeuhprI9Q2VBMrVDgJKCBZ6HRpZogtDhtrGahesUpoITKuE1vKEXbz0LZH-rD4v3TRk68eRop_X3LUIGlCoAj--gs_zmmJ5WyeEaGqJBgo6P6C1n7zrtmmYKO26fz9awKcDoGxpDImiHfJ_DhBblH8Bw6WFIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222653190</pqid></control><display><type>article</type><title>Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds</title><source>Springer Link</source><creator>DAGENAIS, Claude ; JIAN ZONG ; DUCHARME, Julie ; POLLACK, Gary M</creator><creatorcontrib>DAGENAIS, Claude ; JIAN ZONG ; DUCHARME, Julie ; POLLACK, Gary M</creatorcontrib><description>This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil. Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain perfusion. Brain:plasma distribution of substrates after i.v. administration was determined in both strains. Genetic disruption of mdr1a P-gp resulted in 1.3-, 6.6- and 14-fold increases in Clup for morphine, verapamil and quinidine, respectively. With the exception of small differences for verapamil, gender did not affect Clup. Saturable transport of verapamil and quinidine was observed only in P-gp-competent mice, with apparent IC50 values for efflux of 8.6 +/- 2.3 microM and 36 +/- 2 microM, respectively. Verapamil Clup was approximately 50% higher in mdr1a(+/-) vs. mdr1a(+/+) mice; no such difference was observed for quinidine. In P-gp-competent mice, uptake of verapamil and quinidine was unaffected by organic vehicles. Plasma decreased VER Clup to a greater extent in the presence of P-gp. The influence of P-gp in situ was lower than, but correlated with, the effect in vivo. P-gp decreases Clup of morphine, verapamil and quinidine in situ with little or no influence of gender, but this effect cannot fully account for the effects of P-gp in vivo. P-gp is the only saturable transport mechanism for verapamil and quinidine at the murine blood-brain barrier. The influence of protein binding on Clup may be enhanced by P-gp-mediated efflux.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1023/A:1010984110732</identifier><identifier>PMID: 11496955</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Anesthetics. Neuromuscular blocking agents ; Animals ; Antiarythmic agents ; Antimalarials - blood ; Antimalarials - pharmacokinetics ; ATP Binding Cassette Transporter, Subfamily B - deficiency ; ATP Binding Cassette Transporter, Subfamily B - genetics ; ATP Binding Cassette Transporter, Subfamily B - pharmacokinetics ; ATP-Binding Cassette Transporters - genetics ; ATP-Binding Cassette Transporters - pharmacokinetics ; Biological and medical sciences ; Blood-brain barrier ; Blood-Brain Barrier - genetics ; Brain - metabolism ; Brain research ; Calcium Channel Blockers - blood ; Calcium Channel Blockers - pharmacokinetics ; Cardiovascular system ; Dose-Response Relationship, Drug ; Female ; Gender differences ; Glycoproteins ; Laboratory animals ; Male ; Medical sciences ; Mice ; Mice, Knockout ; Morphine ; Morphine - blood ; Morphine - pharmacokinetics ; Narcotics - blood ; Narcotics - pharmacokinetics ; Neuropharmacology ; Perfusion - methods ; Pharmacology. Drug treatments ; Plasma ; Quinidine - blood ; Quinidine - pharmacokinetics ; Sex Characteristics ; Substrate Specificity - genetics ; Verapamil - blood ; Verapamil - pharmacokinetics</subject><ispartof>Pharmaceutical research, 2001-07, Vol.18 (7), p.957-963</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Jul 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1101171$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11496955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAGENAIS, Claude</creatorcontrib><creatorcontrib>JIAN ZONG</creatorcontrib><creatorcontrib>DUCHARME, Julie</creatorcontrib><creatorcontrib>POLLACK, Gary M</creatorcontrib><title>Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil. Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain perfusion. Brain:plasma distribution of substrates after i.v. administration was determined in both strains. Genetic disruption of mdr1a P-gp resulted in 1.3-, 6.6- and 14-fold increases in Clup for morphine, verapamil and quinidine, respectively. With the exception of small differences for verapamil, gender did not affect Clup. Saturable transport of verapamil and quinidine was observed only in P-gp-competent mice, with apparent IC50 values for efflux of 8.6 +/- 2.3 microM and 36 +/- 2 microM, respectively. Verapamil Clup was approximately 50% higher in mdr1a(+/-) vs. mdr1a(+/+) mice; no such difference was observed for quinidine. In P-gp-competent mice, uptake of verapamil and quinidine was unaffected by organic vehicles. Plasma decreased VER Clup to a greater extent in the presence of P-gp. The influence of P-gp in situ was lower than, but correlated with, the effect in vivo. P-gp decreases Clup of morphine, verapamil and quinidine in situ with little or no influence of gender, but this effect cannot fully account for the effects of P-gp in vivo. P-gp is the only saturable transport mechanism for verapamil and quinidine at the murine blood-brain barrier. The influence of protein binding on Clup may be enhanced by P-gp-mediated efflux.</description><subject>Anesthetics. Neuromuscular blocking agents</subject><subject>Animals</subject><subject>Antiarythmic agents</subject><subject>Antimalarials - blood</subject><subject>Antimalarials - pharmacokinetics</subject><subject>ATP Binding Cassette Transporter, Subfamily B - deficiency</subject><subject>ATP Binding Cassette Transporter, Subfamily B - genetics</subject><subject>ATP Binding Cassette Transporter, Subfamily B - pharmacokinetics</subject><subject>ATP-Binding Cassette Transporters - genetics</subject><subject>ATP-Binding Cassette Transporters - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Blood-brain barrier</subject><subject>Blood-Brain Barrier - genetics</subject><subject>Brain - metabolism</subject><subject>Brain research</subject><subject>Calcium Channel Blockers - blood</subject><subject>Calcium Channel Blockers - pharmacokinetics</subject><subject>Cardiovascular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Gender differences</subject><subject>Glycoproteins</subject><subject>Laboratory animals</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Morphine</subject><subject>Morphine - blood</subject><subject>Morphine - pharmacokinetics</subject><subject>Narcotics - blood</subject><subject>Narcotics - pharmacokinetics</subject><subject>Neuropharmacology</subject><subject>Perfusion - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasma</subject><subject>Quinidine - blood</subject><subject>Quinidine - pharmacokinetics</subject><subject>Sex Characteristics</subject><subject>Substrate Specificity - genetics</subject><subject>Verapamil - blood</subject><subject>Verapamil - pharmacokinetics</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpd0E1r3DAQBmBRWppNmnNuQZSSU9zOSLIt5RZCkhYC7aGF3MxYH8GpLW8l-7D_vlqyhRIQSIhnZvSKsTOEzwhCfrm-QkAwWiFCK8UbtsG6lZUB9fiWbaAVqtKtwiN2nPMzAGg06j07QlSmMXW9YbvbELxd-Bz45BIS_1E9jTs7b9O8-CHyJx89d0NO63YZ5ni5v3A-XXKKjue1z0uixXM7R-vj_lwQL6tPVKpLEf32--bZj2WMd0VO23mNLn9g7wKN2Z8e9hP26-72583X6uH7_beb64fKSg1Lhb2osTeuhprI9Q2VBMrVDgJKCBZ6HRpZogtDhtrGahesUpoITKuE1vKEXbz0LZH-rD4v3TRk68eRop_X3LUIGlCoAj--gs_zmmJ5WyeEaGqJBgo6P6C1n7zrtmmYKO26fz9awKcDoGxpDImiHfJ_DhBblH8Bw6WFIg</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>DAGENAIS, Claude</creator><creator>JIAN ZONG</creator><creator>DUCHARME, Julie</creator><creator>POLLACK, Gary M</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20010701</creationdate><title>Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds</title><author>DAGENAIS, Claude ; JIAN ZONG ; DUCHARME, Julie ; POLLACK, Gary M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Anesthetics. Neuromuscular blocking agents</topic><topic>Animals</topic><topic>Antiarythmic agents</topic><topic>Antimalarials - blood</topic><topic>Antimalarials - pharmacokinetics</topic><topic>ATP Binding Cassette Transporter, Subfamily B - deficiency</topic><topic>ATP Binding Cassette Transporter, Subfamily B - genetics</topic><topic>ATP Binding Cassette Transporter, Subfamily B - pharmacokinetics</topic><topic>ATP-Binding Cassette Transporters - genetics</topic><topic>ATP-Binding Cassette Transporters - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Blood-brain barrier</topic><topic>Blood-Brain Barrier - genetics</topic><topic>Brain - metabolism</topic><topic>Brain research</topic><topic>Calcium Channel Blockers - blood</topic><topic>Calcium Channel Blockers - pharmacokinetics</topic><topic>Cardiovascular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Gender differences</topic><topic>Glycoproteins</topic><topic>Laboratory animals</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Morphine</topic><topic>Morphine - blood</topic><topic>Morphine - pharmacokinetics</topic><topic>Narcotics - blood</topic><topic>Narcotics - pharmacokinetics</topic><topic>Neuropharmacology</topic><topic>Perfusion - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasma</topic><topic>Quinidine - blood</topic><topic>Quinidine - pharmacokinetics</topic><topic>Sex Characteristics</topic><topic>Substrate Specificity - genetics</topic><topic>Verapamil - blood</topic><topic>Verapamil - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAGENAIS, Claude</creatorcontrib><creatorcontrib>JIAN ZONG</creatorcontrib><creatorcontrib>DUCHARME, Julie</creatorcontrib><creatorcontrib>POLLACK, Gary M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAGENAIS, Claude</au><au>JIAN ZONG</au><au>DUCHARME, Julie</au><au>POLLACK, Gary M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>18</volume><issue>7</issue><spage>957</spage><epage>963</epage><pages>957-963</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>This study assessed the influence of mdr1a P-glycoprotein (P-gp) gene disruption, gender and concentration on initial brain uptake clearance (Clup) of morphine, quinidine and verapamil. Clup of radiolabeled substrates was determined in P-gp-competent and deficient [mdr1a(-/-)] mice by in situ brain perfusion. Brain:plasma distribution of substrates after i.v. administration was determined in both strains. Genetic disruption of mdr1a P-gp resulted in 1.3-, 6.6- and 14-fold increases in Clup for morphine, verapamil and quinidine, respectively. With the exception of small differences for verapamil, gender did not affect Clup. Saturable transport of verapamil and quinidine was observed only in P-gp-competent mice, with apparent IC50 values for efflux of 8.6 +/- 2.3 microM and 36 +/- 2 microM, respectively. Verapamil Clup was approximately 50% higher in mdr1a(+/-) vs. mdr1a(+/+) mice; no such difference was observed for quinidine. In P-gp-competent mice, uptake of verapamil and quinidine was unaffected by organic vehicles. Plasma decreased VER Clup to a greater extent in the presence of P-gp. The influence of P-gp in situ was lower than, but correlated with, the effect in vivo. P-gp decreases Clup of morphine, verapamil and quinidine in situ with little or no influence of gender, but this effect cannot fully account for the effects of P-gp in vivo. P-gp is the only saturable transport mechanism for verapamil and quinidine at the murine blood-brain barrier. The influence of protein binding on Clup may be enhanced by P-gp-mediated efflux.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>11496955</pmid><doi>10.1023/A:1010984110732</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-8741
ispartof Pharmaceutical research, 2001-07, Vol.18 (7), p.957-963
issn 0724-8741
1573-904X
language eng
recordid cdi_proquest_miscellaneous_71080124
source Springer Link
subjects Anesthetics. Neuromuscular blocking agents
Animals
Antiarythmic agents
Antimalarials - blood
Antimalarials - pharmacokinetics
ATP Binding Cassette Transporter, Subfamily B - deficiency
ATP Binding Cassette Transporter, Subfamily B - genetics
ATP Binding Cassette Transporter, Subfamily B - pharmacokinetics
ATP-Binding Cassette Transporters - genetics
ATP-Binding Cassette Transporters - pharmacokinetics
Biological and medical sciences
Blood-brain barrier
Blood-Brain Barrier - genetics
Brain - metabolism
Brain research
Calcium Channel Blockers - blood
Calcium Channel Blockers - pharmacokinetics
Cardiovascular system
Dose-Response Relationship, Drug
Female
Gender differences
Glycoproteins
Laboratory animals
Male
Medical sciences
Mice
Mice, Knockout
Morphine
Morphine - blood
Morphine - pharmacokinetics
Narcotics - blood
Narcotics - pharmacokinetics
Neuropharmacology
Perfusion - methods
Pharmacology. Drug treatments
Plasma
Quinidine - blood
Quinidine - pharmacokinetics
Sex Characteristics
Substrate Specificity - genetics
Verapamil - blood
Verapamil - pharmacokinetics
title Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A04%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20mdr1a%20P-glycoprotein%20gene%20disruption,%20gender,%20and%20substrate%20concentration%20on%20brain%20uptake%20of%20selected%20compounds&rft.jtitle=Pharmaceutical%20research&rft.au=DAGENAIS,%20Claude&rft.date=2001-07-01&rft.volume=18&rft.issue=7&rft.spage=957&rft.epage=963&rft.pages=957-963&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1023/A:1010984110732&rft_dat=%3Cproquest_pubme%3E71080124%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c380t-1b251b9d505aadb6a1944d5d0f130fc0b8f6373229a9a76c8dfc448aa09742883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222653190&rft_id=info:pmid/11496955&rfr_iscdi=true